Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物) | Zendy

Grunberger George | Zendy

Open Access

Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)

Author(s) -

Grunberger George

Publication year - 2013

Publication title -

journal of diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.949

H-Index - 43

eISSN - 1753-0407

pISSN - 1753-0393

DOI - 10.1111/1753-0407.12046

Subject(s) - incretin , medicine , type 2 diabetes mellitus , diabetes mellitus , glucagon like peptide 1 , exenatide , dipeptidyl peptidase 4 , saxagliptin , sitagliptin , type 2 diabetes , intensive care medicine , pharmacology , endocrinology

The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon‐like peptide‐1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called “incretin defect” in patients with T2DM .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research